2
Androgen receptor remains critical for cell-cycle progression in androgen-independent CWR22 prostate cancer cells: Yuan X, Li T, Wang H, Zhang T, Barua M, Borgesi RA, Bubley GJ, Lu ML, Balk SP, Hematology/Oncology Division, Beth Israel Deaconess Medical C
14
Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma—Long-term results of phase III RTOG 85-31: Pilepich MV, Winter K, Lawton CA, Krisch RE, Wolkov HB, Movsas B, Hug EB, Asbell SO, Grignon D, University of California, Los Angeles